The feasibility of this model is supported by experimental evidences that Dkk1 is epigenetically silenced in many tumors including gastrointestinal tumors [43], [44], cervical cancers [45], leukemia [46], and medulloblastoma [47]. Here, DKK1 is linked to digestive system neoplasm.